STOCK TITAN

Apellis (NASDAQ: APLS) insider plans 2203-share sale after 2618 sold

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Apellis Pharmaceuticals insider plans to sell additional shares under Rule 144. A notice was filed to sell 2203 shares of common stock through Fidelity Brokerage Services LLC on or about 01/20/2026 on the NASDAQ market, with an aggregate market value of 43,603.76. The issuer had 126,525,218 common shares outstanding.

The 2203 shares to be sold were acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation. Over the prior three months, Nur Nicholson sold an additional 2618 common shares for gross proceeds of 58,086.09. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about Apellis Pharmaceuticals.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Apellis (APLS) Form 144 filing disclose?

The Form 144 filing discloses an insider’s intent to sell 2203 shares of Apellis common stock on or about 01/20/2026 on the NASDAQ market under Rule 144.

How many Apellis (APLS) shares are planned to be sold in this Form 144?

The notice covers a planned sale of 2203 Apellis common shares, with an indicated aggregate market value of 43,603.76.

How were the Apellis (APLS) shares acquired that are being sold?

The 2203 Apellis shares were acquired on 01/16/2026 via restricted stock vesting from the issuer as compensation.

Has the Apellis (APLS) insider sold other shares recently?

Yes. During the past three months, Nur Nicholson sold 2618 Apellis common shares for gross proceeds of 58,086.09.

How many Apellis (APLS) shares were outstanding in this Form 144?

The filing reports that 126,525,218 Apellis common shares were outstanding for the class of securities referenced.

What representation does the seller make in the Apellis (APLS) Form 144?

By signing the notice, the seller represents they do not know of any material adverse information about Apellis’s current or prospective operations that has not been publicly disclosed.
Apellis Pharmace

NASDAQ:APLS

APLS Rankings

APLS Latest News

APLS Latest SEC Filings

APLS Stock Data

2.59B
106.56M
13.68%
105.74%
16.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM